Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial - PubMed (original) (raw)
Multicenter Study
. 2011 Aug 30;58(10):1057-67.
doi: 10.1016/j.jacc.2011.06.006.
Christian Mueller, Richard M Nowak, W Frank Peacock, Piotr Ponikowski, Martin Mockel, Christopher Hogan, Alan H B Wu, Mark Richards, Paul Clopton, Gerasimos S Filippatos, Salvatore Di Somma, Inder Anand, Leong L Ng, Lori B Daniels, Sean-Xavier Neath, Robert Christenson, Mihael Potocki, James McCord, Oliver Hartmann, Nils G Morgenthaler, Stefan D Anker
Affiliations
- PMID: 21867843
- DOI: 10.1016/j.jacc.2011.06.006
Free article
Multicenter Study
Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial
Alan Maisel et al. J Am Coll Cardiol. 2011.
Free article
Abstract
Objectives: The aim of this study was to determine the prognostic utility of midregion proadrenomedullin (MR-proADM) in all patients, cardiac and noncardiac, presenting with acute shortness of breath.
Background: The recently published BACH (Biomarkers in Acute Heart Failure) study demonstrated that MR-proADM had superior accuracy for predicting 90-day mortality compared with B-type natriuretic peptide (area under the curve: 0.674 vs. 0.606, respectively, p < 0.001) in acute heart failure.
Methods: The BACH trial was a prospective, 15-center, international study of 1,641 patients presenting to the emergency department with dyspnea. Using this dataset, the prognostic accuracy of MR-proADM was evaluated in all patients enrolled for predicting 90-day mortality with respect to other biomarkers, the added value in addition to clinical variables, as well as the added value of additional measurements during hospital admission.
Results: Compared with B-type natriuretic peptide or troponin, MR-proADM was superior for predicting 90-day all-cause mortality in patients presenting with acute dyspnea (c index = 0.755, p < 0.0001). Furthermore, MR-proADM added significantly to all clinical variables (all adjusted hazard ratios: >3.28), and it was also superior to all other biomarkers. MR-proADM added significantly to the best clinical model (bootstrap-corrected c index increase: 0.775 to 0.807; adjusted standardized hazard ratio: 2.59; 95% confidence interval: 1.91 to 3.50; p < 0.0001). Within the model, MR-proADM was the biggest contributor to the predictive performance, with a net reclassification improvement of 8.9%. Serial evaluation of MR-proADM performed in patients admitted provided a significant added value compared with a model with admission values only (p = 0.0005). More than one-third of patients originally at high risk could be identified by the biomarker evaluation at discharge as low-risk patients.
Conclusions: MR-proADM identifies patients with high 90-day mortality and adds prognostic value to natriuretic peptides in patients presenting with acute shortness of breath. Serial measurement of this biomarker may also prove useful for monitoring, although further studies will be required. (Biomarkers in Acute Heart Failure [BACH]; NCT00537628).
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
- Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Maisel A, et al. J Am Coll Cardiol. 2010 May 11;55(19):2062-76. doi: 10.1016/j.jacc.2010.02.025. J Am Coll Cardiol. 2010. PMID: 20447528 Clinical Trial. - Short-term mortality risk in emergency department acute heart failure.
Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, Mueller C, Ponikowski P, Möckel M, Hogan C, Wu AH, Richards M, Filippatos GS, Anand I, Ng LL, Daniels LB, Morgenthaler N, Anker SD, Maisel AS. Peacock WF, et al. Acad Emerg Med. 2011 Sep;18(9):947-58. doi: 10.1111/j.1553-2712.2011.01150.x. Acad Emerg Med. 2011. PMID: 21906204 - Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F, Russo V, De Berardinis B, Numeroso F, Catania P, Cervellin G, Nigra SG, Geraci F, Bressan MA, Guerrini S, Cavazza M, Folli C, Monzani V, Battista S, Mengozzi G, Noto P, Carpinteri G, Semplicini A, Stella F, Ingrassia S, Moscatelli P, Giuntini P, Salerno G, Cardelli P, Di Somma S. Travaglino F, et al. Am J Emerg Med. 2014 Apr;32(4):334-41. doi: 10.1016/j.ajem.2013.12.045. Epub 2014 Jan 3. Am J Emerg Med. 2014. PMID: 24559907 - Role of biomarkers in patients with dyspnea.
Gori CS, Magrini L, Travaglino F, Di Somma S. Gori CS, et al. Eur Rev Med Pharmacol Sci. 2011 Feb;15(2):229-40. Eur Rev Med Pharmacol Sci. 2011. PMID: 21434492 Review. - Novel biomarkers in acute heart failure: MR-pro-adrenomedullin.
Peacock WF. Peacock WF. Clin Chem Lab Med. 2014 Oct;52(10):1433-5. doi: 10.1515/cclm-2014-0222. Clin Chem Lab Med. 2014. PMID: 24756062 Review.
Cited by
- Prognostic utility of mid-regional pro-adrenomedullin and growth differentiation factor 15 in patients undergoing transfemoral transcatheter aortic valve implantation.
Piayda K, Keranov S, Schulz L, Arsalan M, Liebetrau C, Kim WK, Hofmann FJ, Bauer P, Voss S, Troidl C, Sossalla ST, Hamm CW, Nef HM, Dörr O. Piayda K, et al. Clin Res Cardiol. 2024 Oct 25. doi: 10.1007/s00392-024-02560-w. Online ahead of print. Clin Res Cardiol. 2024. PMID: 39453458 - Nonspecific stress biomarkers for mortality prediction in older emergency department patients presenting with falls: a prospective multicenter observational study.
Terhalle L, Arntz L, Hoffmann F, Arnold I, Hafner L, Picking-Pitasch L, Zuppinger J, Delport Lehnen K, Leuppi J, Somasundaram R, Nickel CH, Bingisser R. Terhalle L, et al. Intern Emerg Med. 2024 Jul 3. doi: 10.1007/s11739-024-03693-6. Online ahead of print. Intern Emerg Med. 2024. PMID: 38960969 - Mid-Regional Proadrenomedullin in COVID-19-May It Act as a Predictor of Prolonged Cardiovascular Complications?
Pietraszko P, Zorawski M, Bielecka E, Sielatycki P, Zbroch E. Pietraszko P, et al. Int J Mol Sci. 2023 Nov 27;24(23):16821. doi: 10.3390/ijms242316821. Int J Mol Sci. 2023. PMID: 38069140 Free PMC article. Review. - How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction?
Çelik A, Kılıçaslan B, Temizhan A, Güvenç TS, Altay H, Çavuşoğlu Y, Yılmaz MB, Yıldırımtürk Ö, Nalbantgil S, Ural D. Çelik A, et al. Anatol J Cardiol. 2023 Jun;27(6):308-318. doi: 10.14744/AnatolJCardiol.2023.3297. Anatol J Cardiol. 2023. PMID: 37257015 Free PMC article. - Clinical Potential of Adrenomedullin Signaling in the Cardiovascular System.
Bálint L, Nelson-Maney NP, Tian Y, Serafin SD, Caron KM. Bálint L, et al. Circ Res. 2023 Apr 28;132(9):1185-1202. doi: 10.1161/CIRCRESAHA.123.321673. Epub 2023 Apr 27. Circ Res. 2023. PMID: 37104556 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous